Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (DE:7AY1)
FRANKFURT:7AY1
RESEARCH TOOLSreports
Holding DE:7AY1?
Track your performance easily
7AY1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.06 - €9.80
Previous Close€1.06
Volume0.00
Average Volume (3M)1.42K
Market Cap
€38.58M
Enterprise Value-€34.69M
Total Cash (Recent Filing)$78.66M
Total Debt (Recent Filing)$1.71M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Mar 14, 2025EPS Estimate
-€0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding31,195,891
10 Day Avg. Volume309
30 Day Avg. Volume1,421
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.87
Price to Sales (P/S)496.82
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-428.25
Enterprise Value/Gross Profit-428.25
Enterprise Value/Ebitda0.82
Forecast
1Y Price Target
€5.55Price Target Upside421.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Actinium Pharmaceuticals News
PremiumCompany Announcements
Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes
PremiumCompany Announcements
Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress
PremiumCompany Announcements
Actinium Pharmaceuticals Strengthens Board with New Appointment
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive data from the completed P1b combination trial of Actimab-A + CLAG-M showed high rates of response, measurable residual disease negativity, bone marrow transplant access, and improved survival outcomes in high-risk patients.
Regulatory ProgressPartner Immedica has reported favorable conversations with regulatory agencies in Europe and is still expected to file for approval in 2024.
Strategic Development FocusThe company will focus its efforts and deploy capital on continuing development of Actimab-A, Iomab-ACT, preclinical radiopharmaceutical programs, and Ac-225 manufacturing initiatives.
Bears Say
Financial PerformanceDecreasing the terminal growth rate used in risk-adjusted discounted cash flow (DCF) analysis from 2% to -5% to reflect potential headwinds/uncertainty following deprioritization of Iomab-B development.
Regulatory ChallengesThe FDA determined that the SIERRA trial design and analysis are inadequate, and an overall survival benefit in a randomized head-to-head trial would be required for a BLA.
Sales And Funding StrategyATNM does not plan to fund the late-stage Iomab-B trial now required for BLA filing and will instead search for amenable U.S. partners.
---
Options Prices
Currently, No data available
---
Ownership Overview
6.13%
Insiders
8.70% Mutual Funds
1.56% Other Institutional Investors
74.48% Public Companies and
Individual Investors
7AY1 FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was €1.06 and its highest was €9.80 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Currently, no data Available
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Mar 14, 2025 which is in 82 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Nov 18, 2024. The company reported -€0.352 earnings per share for the quarter, beating the consensus estimate of -€0.367 by €0.014.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate is -€0.36.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,195,890 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -€0.352 in its last earnings report, beating expectations of -€0.367. Following the earnings report the stock price went down -7.99%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Among the largest hedge funds holding Actinium Pharmaceuticals’s share is Royce & Associates LLC. It holds Actinium Pharmaceuticals’s shares valued at 94K.
---
Actinium Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€5.55 (421.92% Upside)
€5.55 (421.92% Upside)
Blogger Sentiment
Bullish
DE:7AY1 Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.25%
12-Months-Change
Fundamentals
Return on Equity
-100.05%
Trailing 12-Months
Asset Growth
-7.68%
Trailing 12-Months
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
---
7AY1 Stock 12 Month Forecast
Average Price Target
€5.55
▲(421.92% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
ADC Therapeutics
―
Cellectar Biosciences
―
Cellectis SA
―
Advaxis
―
Best Analysts Covering 7AY1
1 Year
1 Year Success Rate
3/17 ratings generated profit
1 Year Average Return
-49.45%
reiterated a buy rating 27 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 17.65% of your transactions generating a profit, with an average return of -49.45% per trade.
---